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Abstract 
Background: Improved outcomes in patients with diabetes mellitus undergoing percutaneous coronary interven‑
tion remain an unmet clinical need. We assessed the long‑term efficacy and safety of novel polymer‑free sirolimus‑ 
and probucol‑eluting stent in diabetic patients enrolled in intracoronary stenting and angiographic results: test 
efficacy of sirolimus‑ and probucol‑eluting versus zotarolimus‑eluting stents 5 trial.
Methods: In a pre‑specified subgroup analysis, outcomes of diabetic patients treated with a sirolimus‑ and probucol‑
eluting stent or a second‑generation zotarolimus‑eluting stent were compared. The primary endpoint was a device‑
oriented composite outcome comprising cardiac death, target vessel‑related myocardial infarction (MI), or target 
lesion revascularization (TLR) at 5‑year follow‑up. Event‑free survival was assessed using the Kaplan–Meier method. 
Hazard ratios (HR) and 95 % confidence intervals (CI) were estimated from univariate Cox proportional hazards 
models.
Results: A total of 870 patients with diabetes mellitus were treated with either a sirolimus‑ and probucol‑eluting 
stent (n = 575) or a second‑generation zotarolimus‑eluting stent (n = 295). At 5 years, the rate of device‑oriented 
composite endpoint was comparable between the sirolimus‑ and probucol‑eluting stent and the second‑generation 
zotarolimus‑eluting stent (32.9 versus 33.4 %, HR 0.88, 95 % CI 0.76–1.26). No significant differences were observed 
between the sirolimus‑ and probucol‑eluting stent and the second‑generation zotarolimus‑eluting stent groups in 
the incidence of cardiac death (15.6 versus 16.7 % HR 0.92, 95 % CI 0.63–1.32), target‑vessel MI (4.6 versus 6.6 %, HR 
0.73, 95 % CI 0.40–1.34), and TLR (18.6 versus 18.8 %, HR 1.00, 95 % CI, 0.72–1.41). The rate of definite or probable stent 
thrombosis was low and similar in both groups (2.5 versus 2.6 %, HR 1.02, 95 % CI, 0.41–2.52).
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Background
High rates of adverse events remain a cause of concern in 
patients with diabetes mellitus after percutaneous coro-
nary intervention for obstructive coronary artery disease 
[1, 2]. Second-generation durable polymer drug-eluting 
stents (DES), including a durable polymer zotarolimus-
eluting stent, have demonstrated good efficacy in the 
treatment of coronary artery disease in diabetic patients 
[3, 4]. However, persistent inflammatory response to 
durable polymer coatings of DES is recognized as a 
leading cause of delayed arterial healing and one of the 
key factors underlying late stent failure in patients who 
undergo DES implantation [5, 6]. Indeed, this issue is of 
particular relevance in the setting of diabetic patients 
with high atherothrombotic risk [2, 7].
Against this background polymer-free DES showed 
non-inferior short-term angiographic outcomes in com-
parison with a durable polymer-based everolimus-eluting 
stent in the setting of diabetic patients [8]. However, the 
efficacy and safety of polymer-free DES compared with 
durable polymer-based second-generation DES in dia-
betic patients are poorly defined and very long-term out-
comes are underexplored with data almost exclusively 
deriving from comparison with outdated first-generation 
polymer-based DES [9].
The intracoronary stenting and angiographic results: 
test efficacy of sirolimus- and probucol-eluting versus 
zotarolimus-eluting stents (ISAR-TEST) 5 trial demon-
strated the non-inferiority of a polymer-free dual drug 
sirolimus- and probucol-eluting stent in comparison 
with a durable polymer DES for the clinical endpoints of 
interest at 1  year follow up [10]. In addition, long-term 
follow-up of patients enrolled in this trial showed con-
sistent results over time with comparable safety and effi-
cacy between the two devices at 5  years follow up [11]. 
The aim of our study was to assess 5-year clinical out-
comes of patients with diabetes mellitus who underwent 
angioplasty with a polymer-free dual drug sirolimus- and 
probucol-eluting stent or a second-generation durable 
polymer zotarolimus-eluting stent implantation enrolled 
in the ISAR-TEST 5 trial.
Methods
Study population and study protocol
The primary analysis of the ISAR-TEST 5 clinical trial 
was previously reported [10]. Patients with diabetes 
mellitus represented a pre-specified subgroup of interest 
according to the trial protocol. In brief, the ISAR-TEST 
5 trial was a randomized, non-inferiority trial conducted 
between February 2008 and August 2009, in which 3002 
patients with ischemic symptoms or evidence of induc-
ible or spontaneous myocardial ischemia and one or 
more  ≥50  % de novo stenosis located in native coro-
nary vessels were assigned in a 2:1 treatment allocation 
to receive either a polymer-free dual drug sirolimus- and 
probucol-eluting stent (backbone Yukon stent, Trans-
lumina, Hechingen, Germany; stent currently commer-
cially available as Coroflex Isar stent, B. Braun Melsungen 
AG, Melsungen, Germany) or a second-generation dura-
ble polymer zotarolimus-eluting stent (Endeavor Reso-
lute, Medtronic Vascular, Santa Rosa, Ca, USA). Minimal 
exclusion criteria were applied, with exclusion only of 
patients presenting left main stenosis, cardiogenic shock, 
malignancies, life expectancy  <12  months, known aller-
gies to study medication and pregnancy. Randomization 
sequence was computer generated with allocation con-
cealment by means of sealed opaque envelopes. Rand-
omization was done immediately after crossing the lesion 
with the guide-wire. In case of multiple lesions requiring 
intervention, the same assigned stent was to be implanted 
in all lesions.
The trial was registered at http://www.clinicaltrials.
gov. (trial identifier: NCT00598533). The study was con-
ducted in accordance with the provisions of the Declara-
tion of Helsinki and with the International Conference on 
Harmonization Good Clinical Practices. The trial proto-
col was approved by the institutional ethics committee 
of the participating centers and all included patients pro-
vided specific written informed consent.
Patients were systematically evaluated at 1, 12, 24 and 
60  months by telephone call or office visit. All events 
were adjudicated and classified by an event adjudication 
committee unaware of treatment allocation. According 
to the trial protocol, follow-up coronary angiography was 
scheduled at 6–8  months and both off-line quantitative 
coronary angiography and qualitative assessment were 
performed in an independent core laboratory (ISARE-
SEARCH Center, Munich, Germany).
Study devices and anti‑thrombotic medications
The polymer-free stent platform consists of a pre-
mounted, thin strut (87 µm), sand-blasted, 316L stainless 
Conclusions: In patients with diabetes the long‑term efficacy and safety of a polymer‑free sirolimus‑ and probucol‑
eluting stent were comparable to a second‑generation durable polymer zotarolimus‑eluting stent.
Trial registration ClinicalTrials.gov NCT00598533. Registered 10 January 2008
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steel microporous stent coated with a matrix of sirolimus 
(0.7 %) and probucol (0.7 %) [10, 12, 13]. The distribution 
concentration of sirolimus is 120  mg/cm2 stent and of 
probucol is 100 mg/cm2. Non-clinical testing showed that 
no traces of sirolimus or probucol are observable beyond 
6–8 weeks [13]. The second-generation durable polymer 
zotarolimus-eluting stent uses a bare metal cobalt-chro-
mium platform coated with zotarolimus and the BioLinx 
polymer system [14].
An oral loading dose of 600-mg clopidogrel was admin-
istered to all patients at least 2 h before the intervention, 
regardless of whether the patient was taking clopidogrel 
before being admitted. During the procedure, intrave-
nous aspirin, heparin or bivalirudin, and glycoprotein 
IIb/IIIa inhibitor administration was at the discretion of 
the operators. After the intervention, all patients, regard-
less of treatment allocation, were prescribed 200 mg/day 
aspirin indefinitely, clopidogrel 150 mg for the first 3 days 
or until discharge followed by 75  mg/day for at least 
6 months.
End points and definitions
The primary endpoint of ISAR-TEST 5 was the device-
oriented composite of cardiac death, target vessel-related 
myocardial infarction, or target lesion revascularization 
at 5  years (final study follow up). Secondary endpoints 
were as follows: cardiac death, all-cause death, target ves-
sel myocardial infarction, any myocardial infarction, tar-
get lesion revascularization, any revascularization, target 
vessel revascularization and the incidence of definite/
probable stent thrombosis (by Academic Research Con-
sortium definition) in the diabetic subgroup at 5  years. 
Detailed definitions of endpoints have been previously 
reported [10].
Statistical analysis
The analysis of primary and secondary endpoints was 
planned to be performed on an intention-to-treat basis. 
Continuous data are presented as mean (standard devia-
tion) or median (25th–75th percentiles) according to 
data distribution testing by the Kolmogorov–Smirnov 
test. Categorical data are presented as counts and pro-
portions (%). Differences of clinical characteristics 
between groups were inspected using the Student’s t 
or Wilcoxon rank sum test for continuous variables 
and the Chi squared or Fisher’s exact test for categori-
cal variables (patient-level). Angiographic differences 
between groups were compared using generalized esti-
mating equations for non-normally distributed data [15], 
in order to address intra-patient correlation in patients 
who underwent multi-lesion intervention. Event-free 
survival was assessed using the Kaplan–Meier method 
and differences were quantified by the log-rank test. 
Hazard ratios (HR) with accompanying 95 % confidence 
intervals (CI) were estimated from univariate Cox pro-
portional hazards models. The proportional hazards 
assumption checked by the method of Grambsch and 
Therneau [16] was fulfilled in all cases in which we used 
Cox proportional hazards models. Statistical software 
S-PLUS, version 4.5 (S-PLUS, Insightful Corp, Seattle, 
Wa, USA) was used for analyses.
Results
Patient, lesion, and procedural characteristics 
and angiographic outcomes
Of a total of 3002 patients enrolled in the ISAR-TEST 
5 trial, 870 patients with diabetes mellitus were identi-
fied: 575 patients were assigned to treatment with poly-
mer-free sirolimus- and probucol-eluting stent and 295 
to durable polymer zotarolimus-eluting stent (Fig.  1). 
The groups were well matched in terms of baseline 
patient and lesion characteristics (Table 1). Prevalence 
of patients requiring insulin treatment (P =  0.43) and 
oral anti-diabetic therapy only (P = 0.94) were compa-
rable between groups. A total of 1288 coronary lesions 
received percutaneous coronary intervention (siroli-
mus- and probucol-eluting stent, n = 849; zotarolimus-
eluting stent, n  =  439). Prevalence of patients with 
multiple lesions which treated with stent implantation 
was comparable between groups (P = 0.61). Procedural 
characteristics were broadly comparable between the 
two groups except post-procedural minimal luminal 
diameter and percent diameter stenosis (Table 2).
Angiographic outcomes at 6–8  months are shown in 
Table 2. In-stent late lumen loss and in-segment percent 
diameter stenosis at angiographic follow-up were not dif-
ferent between the treatment groups.














Fig. 1 Patient flow in this study
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Outcomes at 5 years
Five-year clinical outcomes are shown in Table  3. 
There was no significant difference in the occurrence 
of the primary composite endpoint at 5 years between 
the polymer-free sirolimus- and probucol-eluting 
stent and durable polymer zotarolimus-eluting stent 
groups (32.9 versus 33.4  % respectively, HR  =  0.88, 
95  % CI, 0.76–1.26; P =  0.88)(Fig.  2). In terms of the 
individual components of the primary endpoint, rates 
were similar between the two groups: the composite 
of cardiac death or target vessel myocardial infarction 
was, 19.1 versus 20.1 % respectively (HR 0.94, 95 % CI, 
0.67–1.30; P = 0.70) (Fig. 3a), and target lesion revas-
cularization was, 18.6 versus 18.8  % respectively (HR 
1.00, 95  % CI, 0.72–1.41; P  =  0.98) (Fig.  3b). There 
were also no differences of the incidences of other 
secondary endpoints of all-cause death, any myocar-
dial infarction, any revascularization, and target vessel 
revascularization.
The rate of definite or probable stent thrombosis was 
low and similar in both groups (2.5 versus 2.6 % respec-
tively, HR 1.02, 95 % CI, 0.41–2.52; P = 0.97), with only 
one case occurring in the durable polymer zotarolimus-
eluting stent group after 12 months (Fig. 4).
Table 1 Baseline clinical characteristics
Data shown as mean ± SD, median (25th–75th percentiles), or n (%)
a Data available for 725 patients (86.7 %)
Patient‑level characteristics Sirolimus‑ and probucol‑eluting stent 
(n = 575)
Zotarolimus‑eluting stent (n = 295) P value
Age (years) 69 (61–76) 70 (62–76) 0.40
Female 150 (26.1) 79 (26.8) 0.83
Diabetes mellitus therapy
Insulin 197 (34.0) 109 (37.0) 0.43
Oral antidiabetic drugs 289 (50.0) 149 (51.0) 0.94
Hypertension 547 (95.1) 281 (95.3) 0.94
Hypercholesterolemia 389 (68.0) 188 (64.0) 0.25
Current smoker 105 (18.0) 52 (18.0) 0.82
Prior myocardial infarction 177 (30.8) 85 (28.8) 0.55
Prior bypass surgery 59 (10.3) 34 (11.5) 0.57
Clinical presentation 0.46
Silent ischemia 36 (6.3) 15 (5.1)
Stable angina 324 (56.3) 154 (52.2)
Unstable angina 98 (17.0) 61 (20.7)
Non ST‑segment elevation myocardial infarction 73 (12.7) 45 (15.3)
ST‑segment elevation myocardial infarction 44 (7.7 %) 20 (6.8 %)
Multi‑vessel disease 517 (89.9) 263 (89.2) 0.73
Ejection fraction (%)a 54 (44‑60) 55 (41–61) 0.56
Lesion‑level characteristics Sirolimus‑ and probucol‑eluting stent (n = 849) Zotarolimus‑eluting stent (n = 439) P value
Target vessel 0.11
Left anterior descending 336 (39.6) 196 (44.6)
Left circumflex 236 (27.8) 123 (28.0)
Right coronary artery 277 (32.6) 120 (27.3)
Chronic total occlusion 56 (6.6) 22 (5.0) 0.26
Bifurcation 200 (23.6) 112 (25.5) 0.44
Ostial 152 (17.9) 80 (18.2) 0.89
Complex morphology 626 (74.0) 336 (77.0) 0.27
Lesion length (mm) 16.6 ± 9.5 17.9 ± 10.4 0.07
Reference vessel diameter (mm) 2.75 ± 0.52 2.79 ± 0.51 0.36
Minimal luminal diameter (mm) 0.91 ± 0.50 0.92 ± 0.47 0.83
Percent diameter stenosis (%) 67 ± 16 67 ± 15 0.83
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Discussion
Main findings in this study
In the high-risk subgroup of patients with diabetes mel-
litus enrolled in a large-scale randomized trial with 
broad inclusion criteria, the composite primary end-
point of cardiac death, myocardial infarction-related 
to the target vessel, or target lesion revascularization at 
5-year follow-up in subjects treated with a polymer-free 
sirolimus- and probucol-eluting stent was non-inferior 
compared to that in patients treated with a second-
generation durable polymer zotarolimus-eluting stent. 
Moreover, each of the individual cardiovascular end-
points was comparable between groups. In particular, 
the incidence of stent thrombosis was low and compa-
rable in both treatment groups with few events beyond 
12 months.
Table 2 Procedural characteristics and angiographic outcomes
Data shown as mean ± SD or median (25th–75th percentiles) or n (%)
a Data available for 961 lesions (74.6 %)





Balloon diameter (mm) 3.05 (2.59–3.47) 3.02 (2.60–3.45) 0.82
Stented length (mm) 25 (18–34) 24 (18–33) 0.23
In stent analysis
Post‑procedural minimal luminal diameter (mm) 2.50 ± 0.50 2.57 ± 0.49 0.045
Post‑procedural percent diameter stenosis (%) 12 ± 7 11 ± 7 0.03
At follow‑up minimal luminal diameter (mm)a 2.13 ± 0.73 2.20 ± 0.72 0.18
At follow‑up percent diameter stenosis (%)a 24 ± 22 23 ± 21 0.68
Late lumen loss (mm)a 0.36 ± 0.63 0.36 ± 0.59 0.48
In segment analysis
Post‑procedural minimal luminal diameter (mm) 2.23 ± 0.58 2.26 ± 0.55 0.33
Post‑procedural percent diameter stenosis (%) 22 ± 12 22 ± 12 0.83
At follow‑up minimal luminal diameter (mm)a 1.90 ± 0.70 1.98 ± 0.69 0.10
At follow‑up percent diameter stenosis (%)a 33 ± 20 32 ± 19 0.20
Late lumen loss (mm)a 0.31 ± 0.61 0.26 ± 0.57 0.34
Binary restenosisa 107 (17.0) 57 (17.2) 0.95
Table 3 Clinical results at 5 years
Data shown as n (%) or hazard ratio [95 % CI]






Hazard ratio  
[95 % CI]
P value
Cardiac death, target vessel‑related 
myocardial infarction or target lesion 
revascularization
178 (32.9) 91 (33.4) 0.98 [0.76–1.26] 0.88
Cardiac death or target vessel‑related 
myocardial infarction
101 (19.1) 54 (20.1) 0.94 [0.67–1.30] 0.70
Cardiac death 81 (15.6) 44 (16.7) 0.92 [0.63–1.32] 0.64
Target vessel‑related myocardial infarction 26 (4.6) 18 (6.6) 0.73 [0.40–1.34] 0.31
Target lesion revascularization 100 (18.6) 50 (18.8) 1.00 [0.72–1.41] 0.98
All‑cause death 133 (24.4) 79 (27.8) 0.84 [0.63–1.11] 0.21
Any myocardial infarction 37 (6.5) 21 (7.6) 0.90 [0.53–1.54] 0.70
Any revascularization 234 (43.4) 124 (46.9) 0.92 [0.74–1.15] 0.48
Target vessel revascularization 144 (26.8) 70 (26.2) 0.82 [0.78–1.37] 0.82
Definite or probable stent thrombosis 14 (2.5) 7 (2.6) 1.02 [0.41–2.52] 0.97
Definite stent thrombosis 7 (1.2) 4 (1.6) 0.89 [0.26–3.04] 0.85
Probable stent thrombosis 7 (1.2) 3 (1.0) 1.19 [0.31–4.60] 0.80
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Relationship between polymer coatings and adverse 
cardiac events
In patients with diabetes mellitus undergoing coronary 
stenting, the rates of adverse cardiac events such as in-
stent restenosis, myocardial infarction and cardiac death 
remain high even after implantation of second-genera-
tion DES [1–3]. Moreover, these adverse cardiac events 
rates are higher in diabetic patients who require insu-
lin treatment than in those who do not require it [17]. 
Indeed, higher incidences of in-stent neoatherosclerosis 
and very late stent thrombosis were observed in diabetic 
patients compared with non-diabetic patients [18, 19]. 
Both of the latter processes are likely related to delayed 
arterial healing [20, 21], which is at least in part caused by 
an inflammatory reaction to the polymer coatings used 
on DES [5, 6]. On this basis, polymer-free stent design 
might be an approach particularly well-suited for the 
treatment of coronary artery disease in diabetic patients.
Efficacy and safety of polymer‑free drug‑eluting stents
Prior investigation in diabetic patients showed that a 
polymer-free sirolimus-eluting stent had similar long-
term efficacy and safety compared with a first-generation 
paclitaxel-eluting stent [9]. However, this data was lim-
ited by the fact that the comparator stent was an early-
generation DES with only moderate antirestenotic 
efficacy, which has subsequently fallen out of clinical use. 
In addition, the study stent was coated only with siroli-
mus, an approach that likely does not result in adequate 
clinical efficacy. In our study, in a large cohort of diabetic 
patient we showed comparable clinical efficacy at 5 years 
between a polymer-free sirolimus- and probucol-eluting 
stent compared with a high performance second-genera-
tion durable polymer zotarolimus-eluting stent. As previ-
ously reported the improved angiographic antirestenotic 
efficacy with the polymer-free stent used in our study 
(in comparison with a similar single-drug polymer-free 
stent) are likely due to the incorporation of probucol in 
the stent coating [13, 22]. This compensates for the inher-
ently less favorable drug-release kinetic seen with poly-
mer-free DES. The mechanism of benefit is likely twofold: 
as probucol is highly lipophilic it can retard the release 
of sirolimus from the stent surface and improve tissue 
drug levels, in addition, due to the antioxidant effects of 
probucol it targets a separate component of the resten-









0 1 2 3 4 5
Number at risk
575 456 417 386 350 283
Sirolimus- and
probucol-eluting stent
295 224 210 191 173 144Zotarolimus-eluting stent
Sirolimus- and probucol-eluting stent
Zotarolimus-eluting stent
HR = 0.98 (95% CI, 0.76 – 1.26)
P = 0.88
Fig. 2 Time to event curve in cumulative incidences of primary endpoint. Primary endpoint is the device‑oriented composite of cardiac death, 
target vessel‑related myocardial infarction, or target lesion revascularization. Hazard ratios and P values are derived from Cox proportional hazard 
methods. CI confidence interval, HR hazard ratio
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Fig. 3 Time to event curve in cumulative incidences of the components of primary endpoint (a) the composite of cardiac death, target vessel‑
related myocardial infarction. b Target lesion revascularization. Hazard ratios and P values are derived from Cox proportional hazard methods. CI 
confidence interval, HR hazard ratio
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Importantly, the polymer-free sirolimus- and probucol-
eluting stent also demonstrated a low incidence of stent 
thrombosis out to 5 years. Indeed we observed no cases 
of stent thrombosis beyond 1  year in patients treated 
with the polymer-free stent in this study. On the other 
hand, it should be observed that no clear advantage 
could be seen with polymer-free stents in comparison 
to durable polymer stents with regard to very late stent 
thrombosis. Indeed this is broadly in line with results of 
a recent meta-analysis of both diabetic and nondiabetic 
patients [25], though this lack of difference must be inter-
preted in light of the low event rates in both groups.
With regard to angiographic antirestenotic efficacy, the 
late lumen loss observed in patients with diabetes in our 
study was 0.36  mm (in stent) both with sirolimus- and 
probucol-eluting and zotarolimus-eluting stents. This 
is somewhat higher than in other studies investigat-
ing patients with diabetes. For example in the SPIRIT 
V diabetic study, late loss was 0.19 mm; in the RESOR-
VOIR study, 0.24  mm with everolimus-eluting stent [8, 
26]. Although the reasons for this are unclear, this may 
be related to baseline patient and lesion complexity: the 
inclusion criteria in our study were broader and exclu-
sion criteria were fewer. Moreover, our results may be 
expected to be representative of real-world practice and 
therefore broadly applicable to diabetic patients in a wide 
variety of settings.
Limitations
Our study has several limitations. First, because this is a 
post hoc analysis at 5 years, results must be interpreted 
with caution. Second, despite including 870 patients, 
this substudy was not powered to show a difference in 
the occurrence of the primary endpoint between the two 
groups at 5  years as well as in rarely-occurring individ-
ual endpoints such as stent thrombosis. Third, although 
the target lesion revascularization rates of both stents 
in our study were relatively high, these results were 
likely influenced by requirement for protocol-mandated 
angiographic follow-up. This is known to inflate the rate 
of revascularization in comparison with routine clini-
cal practice. In fact, most cases with target lesion revas-
cularization were observed between 6 and 8  months 
after index intervention. However, despite potential for 
greater absolute differences between stents in trials with 
angiographic follow-up, relative differences observed 
are expected to be real [27]. Fourth, although we recom-
mended patients to continue dual antiplatelet therapy at 
least 12 months, data concerning the actual duration of 
dual anti-platelet therapy received was not captured.
Follow-up time (years)







0 1 2 3 4 5
Number at risk
575 527 497 465 424 352
Sirolimus- and
probucol-eluting stent
295 260 248 233 211 180Zotarolimus-eluting stent
Sirolimus- and probucol-eluting stent
Zotarolimus-eluting stent
HR = 1.02 (95% CI, 0.41 – 2.52)
P = 0.97
Fig. 4 Time to event curve in cumulative incidences of the definite or probable stent thrombosis. Hazard ratios and P values are derived from Cox 
proportional hazard methods
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Conclusions
In the setting of a large-scale randomized trial with broad 
inclusion criteria, cardiovascular outcomes at 5  years 
follow-up of diabetic patients treated with a polymer-free 
sirolimus- and probucol-eluting stent were non-inferior 
to those of patients receiving a second-generation dura-
ble polymer zotarolimus-eluting stent. Rates of stent 
thrombosis were comparable and satisfactory low, with 
few events beyond 12 months.
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